key: cord-0839643-9h47t74j authors: Wang, Gongxin; Lu, Chieh-Ju; Trafford, Andrew W.; Tian, Xiaohui; Flores, Hannali M; Maj, Piotr; Zhang, Kevin; Niu, Yanhong; Wang, Luxi; Du, Yimei; Ji, Xinying; Xu, Yanfang; Wu, Lin; Li, Dan; Herring, Neil; Paterson, David; Huang, Christopher L.-H.; Zhang, Henggui; Lei, Ming; Hao, Guoliang title: Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19 date: 2020-05-28 journal: bioRxiv DOI: 10.1101/2020.05.21.108605 sha: 5e78cb216f1aea1c35580003461e1a99294e2c14 doc_id: 839643 cord_uid: 9h47t74j Aims We investigate mechanisms for potential pro-arrhythmic effects of hydroxychloroquine (HCQ) alone, or combined with azithromycin (AZM), in Covid-19 management supplementing the limited available experimental cardiac safety data. Methods We integrated patch-clamp studies utilizing In Vitro ProArrhythmia Assay (CiPA) Schema IC50 paradigms, molecular modelling, cardiac multi-electrode array and voltage (RH237) mapping, ECG studies, and Ca2+ (Rhod-2 AM) mapping in isolated Langendorff-perfused guinea-pig hearts with human in-silico ion current modelling. Results HCQ blocked IKr and IK1 with IC50s (10±0.6 and 34±5.0 μM) within clinical therapeutic ranges, INa and ICaL at higher IC50s, leaving Ito and IKs unaffected. AZM produced minor inhibition of INa, ICaL, IKs, and IKr,, sparing IK1 and Ito. HCQ+AZM combined inhibited IKr and IK1 with IC50s of 7.7±0.8 μM and 30.4±3.0 μM, sparing INa, ICaL and Ito. Molecular modelling confirmed potential HCQ binding to hERG. HCQ slowed heart rate and ventricular conduction. It prolonged PR, QRS and QT intervals, and caused prolonged, more heterogeneous, action potential durations and intracellular Ca2+ transients. These effects were accentuated with combined HCQ+AZM treatment, which then elicited electrical alternans, re-entrant circuits and wave break. Modelling studies attributed these to integrated HCQ and AZM actions reducing IKr and IK1, thence altering cell Ca2+ homeostasis. Conclusions Combined HCQ+AZM treatment exerts pro-arrhythmic ventricular events by synergetically inhibiting IKr, IKs with resulting effects on cellular Ca2+ signalling, and action potential propagation and duration. These findings provide an electrophysiological basis for recent FDA cardiac safety guidelines cautioning against combining HCQ/AZM when treating Covid-19. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has now infected >5. 18 An initial nonrandomized open label clinical trial of 20 cases, had associated HCQ treatment with viral load reduction or disappearance in COVID-19 patients, effects reinforced by AZM (3) . This subsequently prompted the US Food and Drugs Administration (FDA) authorization of emergency use of CQ or HCQ, alone or in combination with AZM in Covid-19 therapy (4, 5) . Currently, large number of trials of these combinations, with or without the addition of further drugs, are registered worldwide (1, 2). However, several recent studies have flagged cardiac safety concerns for the CQ/HCQ and AZM regime in Covid-19 therapy. Particular concern has arisen regarding potential synergistic effects of HCQ and AZM on QT duration and cardiovascular mortality (6) (7) (8) (9) (10) . Higher mortalities and incidences of prolonged corrected QT (QTc) intervals were reported in patients at a Brazilian hospital receiving the high dose (12 g total dose over 10 days, ~1.2 g/day, giving plasma levels of ~10 µM) than the lower dose of CQ, typified by its use in other conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE). This phase 2b randomized Covid-19 trial was terminated after enrolment of only 81 out of the target of 440 patients owing to occurrences of adverse events (6) . A retrospective data analysis from United States Veterans Health Administration medical centers suggested increased overall mortality even in patients treated with HCQ alone (7) . The largest available analysis from an international consortium on HCQ safety covering over 950,000 patients from six countries declared HCQ safe for short-term use at doses currently used for conditions such as rheumatoid arthritis. However, it urged caution in its use when combined with AZM in view of potential risks of cardiovascular mortality related to QTc prolongation (8) . Two recent reports of 90 and 201 patients hospitalized with COVID-19 treated with HCQ, with or without AZM, associated these drugs with QTc prolongation, especially when used in combination (9, 11) . Although these studies are small, only one case of torsades de pointes was documented and the therapy was seldom discontinued. They suggested that more QT interval monitoring studies should be undertaken before final recommendations can be made (11) . Based on these findings, the FDA issued a cautions warning against use of HCQ or CQ for COVID-19 outside of the hospital setting or a clinical trial, due to risks of heart rhythm problems(4). This does not affect FDAapproved uses in malaria, systemic lupus erythematosus (SLE), and rheumatoid arthritis where they have been used many years. Both HCQ and AZM have been in clinical use alone or in combination in other disease conditions for many years with cardiac safety then not considered a major concern. Currently, there is very limited data evaluating cardiac safety particularly concerning use of HCQ in combination with AZM, although multiple randomized trials are currently in progress evaluating the efficacy of this combination for Covid-19. We therefore explored the cardiac safety of HCQ alone or in combination with AZM using the FDA recommended Comprehensive in Vitro Proarrhythmia Assay (CiPA) protocols to understand arrhythmic mechanisms (12) . Furthermore, we expanded the CiPA protocol by introducing assessments of effects on membrane and Ca 2+ clocks, their interaction and cardiac conduction recently suggested as crucial indicators for ventricular arrhythmogenesis (13, 14) . The four groups of experiments conducted assessed the mechanistic basis for the clinical reports bearing upon cardiac safety of HCQ, whether applied alone or in combination with AZM. The first series of experiments assessed the effects of HCQ (Fig. 1) and AZM alone (Fig. 2) and in combination (Fig. 3) The above findings particularly concerning pharmacological effects on hERG prompted computational molecular docking explorations for possible interactions between HCQ and AZM and a recent hERG homotetramer structure (PDB ID: 5va1; 1) ( Fig.4) . We used scoring docking visual inspection irrespective of the docking protocol. Figure 4 illustrates the HCQ-hERG interaction, derived using three separate rigid-receptor docking methods. HCQ interacts predominantly with Y652 from one or more subunits. Interactions with other residues including F656 but also S624, A653, and S660 occurred less frequently. Variability in observed docking positions could be attributed to the highly symmetric structure of the hERG channel pore constituting the binding site enabling many equivalent positions. In contrast, no interactions were demonstrated between AZM and hERG (data not shown). We then explored the effects of HCQ alone and combined with AZM in the whole heart on electrophysiological activation and recovery, their electrocardiographic correlates and the consequent Ca 2+ signalling processes reflecting excitation-contraction coupling. were treated with the 10 µM HCQ in combination with 10 µM AZM. All these effects were reversed on drug washout (C(i)). 10 µM HCQ significantly decreased conduction velocities of excitation with further decreases in velocity with the 10 µM HCQ and 10 µM AZM combination (C(ii)). Quantification of the corresponding electrocardiogram (ECG) traces (D(i)) demonstrated that both 10 µM HCQ, and 10 µM HCQ in combination with 10 µM AZM, decreased heart rate (HR)(D(i)), and increased QT interval (D(iii)), PR interval (D(iv)) and QRS duration (D(v)). In particular, AZM when combined with HCQ augmented its effects on HR, and QT and PR interval. Together these results suggested that 10 µM HCQ, and 10 µM HCQ and 10 µM AZM combined, exerted synergistic inhibitory effects on heart rate and conduction, and prolonged cardiac repolarisation. We next investigated the effects of HCQ alone and in combination with AZM using optical fluorescence mapping in sinus-paced Langendorff-perfused hearts using the recording and ECG monitoring configurations illustrated in Figure 6A Figure 6C (i)). The latter were attributed to changes late in the CaT records (C(ii)). The quantified CaD90 magnitudes (B(iii)) and dispersions (B(iv)) both increased with 10 but not 1.0 µM HCQ. The combination of 10 µM HCQ with either 1 or 10 µM AZM exerted significantly greater effects than 10 µM HCQ alone. Finally, voltage dye optical mapping studies during ventricular pacing were used to assess susceptibility to arrhythmia induction before and after drug challenge in isolated perfused hearts ( Fig.7A .B). Whilst 10 µM HCQ did not exert detectable arrhythmic effects at the cycle lengths (CL) used, a combination of HCQ and AZM produced AP alternans at 180 ms CL and episodes of non-sustained torsadogenic-like VT at 170 ms CL in 5 out of 5 hearts. The corresponding potentiometric maps obtained during the colour coded timepoints 1-6 are represented in C. At a CL of 170 ms, the conduction maps with HCQ+AZM demonstrated significant disruptions of the normally coherent propagation of excitation waves with evidence of excitation re-entry and wave break. Thus, the electrophysiological changes outlined above associated particularly with HCQ and AZM in combination were associated with a ventricular arrhythmic tendency. To translate the experimental data describing the multi-ion channel blocking effects of HCQ and/or AZM to human ventricular excitation, the ORd model was implemented to reconstruct the impacts of HCQ alone and combined with AZM, on human ventricular action potentials including APD90 and maximal upstroke velocities. The main findings of this study are: (1) Reported therapeutic levels of HCQ blocked multiple human cardiac ion channels, particular hERG (mediating IKr) and Kir2.1 (IK1,) and, to a lesser degree, hNav1.5 (INa). AZM potentiated the effects of HCQ on hERG and Kir2.1. (2) Computational molecular docking studies correspondingly predicted HCQ binding to hERG. Accordingly, (3) at the level of intact hearts, HCQ increased QT intervals as well as ventricular AP and Ca 2+ transient durations and their heterogeneities. However, (4) HCQ further reduced heart rates, A-V and ventricular conduction as well as increasing conduction heterogeneities. All these effects were accentuated by combining HCQ challenge with AZM. Furthermore, (5) The HCQ+AZM combination, but not HCQ alone, then went on to increase susceptibilities to ventricular arrhythmic events consistent with significant clinical cardiac safety risks. (6) Human in-silico modelling of ion channel effects of HCQ and AZM recapitulated the altered APDs but not the reduced conduction. This mechanistic electrophysiological data complements ongoing multiple randomized trials evaluating clinical efficacy and cardiac safety profiles of these drugs as a treatment for Covid-19. The findings directly align with recent FDA guidelines concerning their use. These successive lines of investigation were combined to reach an integrated view of HCQ and AZM action. This began with the approach recommended by the CiPA guidelines (12) Consistent with these experimental findings, computational molecular docking simulations utilizing a recent hERG homotetramer structure (PDB ID: 5va1; 1) demonstrate potential HCQ binding. This is predominantly with Y652 from one or more hERG subunits. Interactions with other residues including F656 but also S624, A653, and S660 occurred less frequently. There was no predicted AZM-hERG binding in the model although this does not discount it occurring in-vivo. Others have also explored the electrophysiological effects of HCQ or AZM on some cardiac ion channels but did so at three times the clinically relevant concentration and above (15, 18) . At the whole heart level, our optical mapping studies demonstrate that HCQ correspondingly prolongs ventricular APD as well as CaD, to extents further exacerbated by combination with AZM. This fulfils expectations from its inhibition of IKr and IK1 and translates to the observed electrocardiographic QT prolongations. It is interesting to note that even prior to the Covid-19 pandemic, series of case reports have led to both HCQ and AZM being listed as definite causes of prolonged QT interval and risk of torsade de pointes for patients with long QT syndrome on crediblemeds.org (19) . Prolonged APD predisposes to early afterdepolarisations (EADs) during the plateau phase of the ventricular action potential, classically attributed to ICaL reactivation (20) . EADs are also more common under conditions of intracellular Ca 2+ overload, including increased sympathetic drive: ICaL can be enhanced by high intracellular Ca 2+ levels and by L-type Ca 2+ channel phosphorylation by CaMKII (21) . EADs may potentially trigger ectopic beats and initiate arrhythmic events given suitable substrate. In addition to these recovery phenomena, we also demonstrate for the first time that HCQ reduces ventricular conduction on multi-electrode arrays and optical mapping recording, and compromise atrioventricular and intraventricular conduction, reflected in prolonged PR intervals and QRS durations, to extents accentuated by further addition of AZM. Such findings are consistent with Na channel block (22) of the kind exemplified clinically by the CAST trials (23) and/or compromised gap junction function (24) . Together, the combination demonstrated here of prolonged and increased dispersions of repolarisation and calcium handling combined with slowed conduction would offer a suitable substrate for sustained re-entrant arrhythmia. Thus, the combined exposure to HCQ and AZM, but not HCQ alone provoked alternans, ventricular tachycardic episodes, and re-entrant excitation following progressively accelerated cardiac pacing. Finally, a validated human ventricular myocyte mathematical model integrated the observed ion channel properties with the effects on action potential and intracellular calcium handling characteristics in intact hearts. It separated whole heart electrophysiological features that were explicable in terms of the single channel properties and those attributable to altered calcium homeostasis. The modelling reproduced effects of surface ion channel function and their interactions forming a 'membrane clock' underlying the measurable electrical activity (Fig. 8C ) (14) . It reproduced the action potential prolongation and consequent prolonged QT intervals with HCQ and the synergistic effects of combining HCQ with AZM, attributing these to their combined effects on IKr and IK1. These latter events have been described as feeding forward into a 'Ca 2+ clock' driving excitation-contraction coupling but whose events exert feedback effects modifying action potential conduction, recovery, and post-recovery stability, exemplified by Ca 2+ feedback effects on Na + channel and gap junction function (Fig. 8C) , as well as longer-term effects on channel expression (13, 25) . The modelling predicted the increased calcium transient magnitudes and durations particularly with HCQ+AZM ( Fig 8C) , but only small changes in maximum upstroke velocity attributable to Na channel blockade. The observed conduction slowing nevertheless could arise from a Ca 2+ -dependent gap junction uncoupling. These results together provide an integrated basis for the electrophysiological and pharmacological effects of HCQ, AZM and their combination. They thereby underpin recent FDA guidelines cautioning against combined HCQ/AZM administration for treatment of Covid-19 on grounds of cardiac safety. Admittedly, physiological though not pro-arrhythmic effects occurred with HCQ administered alone at the ~10 µM concentrations associated with Covid-19 therapy and not at the lower ~1.0 µM HCQ levels associated with therapy for rheumatoid arthritis and SLE. HCQ alone at therapeutic doses thus did not increase incidences of experimental ventricular arrhythmias in healthy hearts. Nevertheless, safety threshold doses could be reduced by accompanying cardiac injury arising from viral toxicity, sepsis, hypoxiarelated myocyte injury, and immune-mediated cytokine storm in Covid-19. Furthermore, AZM potentiated the HCQ toxicity, now producing arrhythmic outcomes. The present findings thus strongly indicate a desirability for monitoring electrocardiographic, including QT, changes and cardiac injury during 4-aminoquinoline-macrolide therapy for Covid-19 patients. All procedures were approved by The Institutional Animals Ethics Committees at Henan University, Kaifeng, China under and the national guidelines under which the institution operates, and also conform with the NIH Guide for the Care and Use of Laboratory Animals. Guinea pigs (male; 300-350 g) were provided by The Experimental Animal Center of the Medical College of Xi'an Jiaotong University and maintained in a pathogen−free facility at Henan University with ad libitum access to food and water. Animals were humanely sacrificed by intraperitoneal injection with 3% pentobarbital sodium (50 mg/kg). The experimental structure of the open hERG channel (PDB ID: 5va1; 1) was selected as a receptor for molecular docking studies. The structure was prepared for docking using Protein Preparation Wizard using default settings including modelling of missing loops using Prime. The loops spanning residues 433-448, 578-582, and 588-602 in each subunit were successfully rebuilt. The centroid of residues Y652 and F656 from every subunit was defined as the centre of the docking binding site. The HCQ structure was obtained from PubChem and prepared for docking using LigPrep. Three separate rigid-receptor docking methods were used including: (i) Glide SP docking, (ii) FlexX docking followed by HYDE re-scoring, and (iii) AutoDock Vina docking with each set to output 20 poses per LigPrep HCQ state. Poses from Glide, FlexX, and AutoDock Vina were also re-scored using RF-Score-VS. Guinea pigs (male; 300-350 g) were humanely killed by intraperitoneal injection with pentobarbital sodium (50 mg/kg). Hearts rapidly excised after thoracotomy were mounted onto a Langendorff perfusion system and perfused with a modified Tyrode's solution (119 NaCl, 25 NaHCO3, 4 KCl, 1.2 KH2PO4, 1 MgCl2, 1.8 CaCl2.2H2O, and 10 D-glucose (mM) equilibrated with 5% CO2 and 95% O2) with the flow rate of 8 ml/min at 37°C. Hearts were perfused and monitored for stability for 20 mins before experimental procedures commenced. After the Langendorff-perfused hearts reached steady state, contraction artefacts were mimimised using blebbistatin (10 µM). Dye loading was aided by pre-perfusion with pluronic F127 (20 % w/v in DMSO). Rh237 (1µg/ml) and Rhod2-AM (1µg/ml) were perfused to enable simultaneous membrane potential and Ca 2+ measurements at 37 ℃ . Stimuli were generated by an isolated constant voltage/current stimulator (VCS3001, MappingLab Ltd., UK). They were delivered with a platinum electrode onto the epicardial apex at an amplitude 1.5 × the diastolic voltage threshold and a 2 ms pulse width. The optical mapping was performed in conjunction with an "alternans mapping" protocol. The heart was consecutively paced at basic cycle lengths (BCL) from 210 with 10 ms decrement until 170 ms. The heart was paced 50 times with 2 ms duration pulses and the optical mapping recording was performed at the last 2 second in each episode. This protocol was performed both before and after drugs were delivered. The O'Hara-Rudy (ORd) human ventricular model (26) was modified to incorporate the actions on multi-channel block of HCQ, including the dose-dependent block of INa,, ICaL,, Ito, IKr, IKs IK1 and the Na + -Ca 2+ exchange current, INCX. This model was selected as it was developed from and validated against experimental data from human ventricular cells and found suitable for studying actions of drugs. The simulations evoked action potentials by a supra-threshold stimulus in control runs and following application of HCQ, and combined application of HCQ and AZM. Action potential time courses characterized by AP durations at 90% repolarisation (APD90) and maximal upstroke velocity (MUP) and the underlying ion channel currents targeted by the drugs were recorded for analysis. All patch clamp recorded data were analyzed using Clampfit 10.6 (Molecular Devices, USA), , where x is the drug concentration, and p is the Hill coefficient. All data are expressed as the means ± SEM. Oneway ANOVA followed by multiple-comparison test was used to evaluate multiple test treatments. A value of p<0.05 was considered to be statistically significant. IC50 denotes the concentration determined for half-maximal inhibitory effects. In the figures, the designations for p values are: *p<0.05, **P<0.01 and ***P<0.001 respectively. The authors have declared that no conflict of interest exists. GH, CL, AT, DP, CLHH, HZ and ML contributed to the study design GW, XT, GH, YN, LW, XJ, GH contributed to the electrophysiological data acquisition. (C) (i) Successive LV isochronal maps before and following addition of 10 µM HCQ and 10 µM HCQ and 10 µM AZM in combination followed by drug washout. (ii) Quantified conduction velocities through these conditions. (D) ECG studies: (i) ECG records obtained before and following application of 10 µM HCQ, and 10 µM HCQ and 10 µM AZM combined, followed by drug washout. (ii)-(v): corresponding measured (ii) heart rates (HR), (iii) QT and (iv) PR intervals and (v) QRS durations (n hearts) * p<0.05, ** p<0.01, *** p<0.001 NIH clinical trial of hydroxychloroquine, a potential therapy for COVID-19, begins Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial Food and Drug Administration Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and selfcontrolled case series study Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting Modernized Classification of Cardiac Antiarrhythmic Drugs Cardiac arrhythmogenesis: a tale of two clocks? Cardiovac Res Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca 2+ current The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies Cardiotoxicity of local anaesthetic agents Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial Determinants of myocardial conduction velocity: implications for arrhythmogenesis Murine Electrophysiological Models of Cardiac Arrhythmogenesis Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation GW, YD, GH, YX, LW, DL and NH contributed to the data analysis and visualization.HF, KZ, HZ contributed to the action potential computer simulation.PM and ML contributed to the molecular docking computer simulation.LW, DP, ML and GH contributed to the funding and resource acquisition.ML and GH contributed to the supervision.All authors contributed to the writing.